APVO (STOCKS)
Aptevo Therapeutics Inc
$4.700000
-0.080000 (-1.67%)
Prev close: $4.780000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Jeffrey G. Lamothe
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5.86M
- Employees
- 37
- P/E (TTM)
- -0.02
- P/B (TTM)
- 0.50
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-6.41 | $-5.71 | -0.6980 | -12.22% |
|
Dec 2025 (Q4)
|
$-0.01 | $-8.25 | +8.2418 | +99.88% |
|
Sep 2025 (Q3)
|
$-33.48 | $-38.37 | +4.8924 | +12.75% |
|
Jun 2025 (Q2)
|
$-151.20 | $-1,527.55 | +1,376.3520 | +90.10% |
Financial Statements
| Research and Development | $14.83M |
| Operating Income/Loss | -$26.67M |
| Income/Loss From Continuing Operations After Tax | -$26.26M |
| Income/Loss From Continuing Operations Before Tax | -$26.26M |
| Net Income/Loss | -$26.26M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$26.26M |
| Net Income/Loss Available To Common Stockholders, Basic | -$27.92M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $1.67M |
| Preferred Stock Dividends And Other Adjustments | $1.67M |
| Basic Earnings Per Share | -$92.89 |
| Diluted Earnings Per Share | -$92.89 |
| Basic Average Shares | 4,267,914 |
| Diluted Average Shares | 4,267,914 |
| Assets | $19.90M |
| Current Assets | $15.98M |
| Prepaid Expenses | $608.00K |
| Other Current Assets | $15.38M |
| Noncurrent Assets | $3.92M |
| Fixed Assets | $268.00K |
| Other Non-current Assets | $3.65M |
| Liabilities | $8.29M |
| Current Liabilities | $4.76M |
| Accounts Payable | $890.00K |
| Wages | $803.00K |
| Other Current Liabilities | $3.07M |
| Noncurrent Liabilities | $3.53M |
| Equity | $11.61M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $11.61M |
| Liabilities And Equity | $19.90M |
| Net Cash Flow From Operating Activities | -$26.98M |
| Net Cash Flow From Operating Activities, Continuing | -$26.98M |
| Net Cash Flow From Investing Activities | -$5.81M |
| Net Cash Flow From Financing Activities | $39.37M |
| Net Cash Flow | $6.58M |
| Net Cash Flow, Continuing | $6.58M |
| Comprehensive Income/Loss | -$26.26M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$26.26M |
| Other Comprehensive Income/Loss | $0.00 |